Transparency Market Research (TMR), in its recent outlook titled, “U.S. Nutraceuticals Market–Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016–2024”., projects that the in terms of value, U.S. Nutraceuticals market revenue will expand at a CAGR of 5.3% during the forecast period. In terms of revenue, the U.S. Nutraceuticals market accounted for US$ 64.8 Bn in 2015 and is anticipated to increase to reach US$ 102.6 Bn by 2024.

On the basis of product, the market is segmented into functional foods, functional beverages and dietary supplements. To capture of the full scope of the market, each of these segments is further divided on the basis of the nature of the product. Functional foods are segmented to probiotics, omega fatty acid fortified foods, branded iodized salt, branded wheat flour and others. Functional beverages segment is further divided into energy drinks, sports drinks, fortified juices, dairy beverages and others. The dietary supplements segment encompasses protein supplements, vitamins and minerals, herbal supplements and others (fatty acids, fibers).

On the basis of product form, the market is segmented into tablets and capsules, liquids, powders and solids/semi-solids. Each product form is indicative of the respective product nature. Dietary supplements are available in all four products form, with tablets and capsules being a major category.

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=22325

Detailed profiles of the manufacturers are included in the scope of the report to evaluate their long-term and short-term strategies, key offerings and recent developments in the Nutraceuticals space. Apart from these, the capacity utilization of all the major players is also included in the report. Key players in the U.S. Nutraceuticals market include General Mills Inc., The Natures Bounty Co. (NBTY), Amway Enterprises, Herbalife International, Inc., Royal DSM NV, Pepsi Co., Groupe Danone, Bayer AG, Abbott Laboratories, Chobani LLC.

LEAVE A REPLY